Oncopeptides Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 69

Employees

  • Stock Symbol
  • ONCO

Stock Symbol

  • Share Price
  • $0.16
  • (As of Friday Closing)

Oncopeptides General Information

Description

Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Luntmakargatan 46, 7 tr
  • 111 37 Stockholm
  • Sweden
+46 08-615
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Luntmakargatan 46, 7 tr
  • 111 37 Stockholm
  • Sweden
+46 08-615

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oncopeptides Stock Performance

As of 20-Nov-2026, Oncopeptides’s stock price is $0.16. Its current market cap is $69.4M with 431M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.16 $0.17 $0.14 - $0.58 $69.4M 431M 5.34M -$0.07

Oncopeptides Financials Summary

As of 30-Sep-2026, Oncopeptides has a trailing 12-month revenue of $11M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 81,152 132,889 17,796 56,750
Revenue 11,015 7,239 2,992 3,314
EBITDA (19,603) (23,003) (25,530) (22,600)
Net Income (20,863) (25,404) (26,911) (23,437)
Total Assets 17,594 14,714 22,132 23,852
Total Debt 14,047 15,148 12,844 13,137
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oncopeptides Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oncopeptides‘s full profile, request access.

Request a free trial

Oncopeptides Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted th
Biotechnology
Stockholm, Sweden
69 As of 2026

Stockholm, Sweden
 

North Chicago, IL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oncopeptides Competitors (14)

One of Oncopeptides’s 14 competitors is Swedish Orphan Biovitrum, a Formerly VC-backed company based in Stockholm, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Swedish Orphan Biovitrum Formerly VC-backed Stockholm, Sweden
AbbVie Corporation North Chicago, IL
Karyopharm Therapeutics Formerly VC-backed Newton, MA
CSL Behring (Biotechnology) Corporation Vienna, Austria
Cellectis Formerly VC-backed Paris, France
You’re viewing 5 of 14 competitors. Get the full list »

Oncopeptides Patents

Oncopeptides Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202413825-D0 Novel therapeutic treatments Inactive 19-Sep-2024
WO-2026057823-A1 Bis-chloroethylamino derivatives for treating leukemia Pending 13-Sep-2024
GB-202410121-D0 Novel polypeptides Inactive 11-Jul-2024
GB-202318674-D0 Novel polypeptides Inactive 06-Dec-2023
GB-202318675-D0 Novel polypeptides Inactive 06-Dec-2023 C07K14/70535
To view Oncopeptides’s complete patent history, request access »

Oncopeptides Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oncopeptides Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oncopeptides‘s full profile, request access.

Request a free trial

Oncopeptides ESG

Risk Overview

Risk Rating

Updated September, 30, 2025

29.34 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Biotechnology

Subindustry

of 394

Rank

Percentile

To view Oncopeptides’s complete esg history, request access »

Oncopeptides FAQs

  • When was Oncopeptides founded?

    Oncopeptides was founded in 2000.

  • Where is Oncopeptides headquartered?

    Oncopeptides is headquartered in Stockholm, Sweden.

  • What is the size of Oncopeptides?

    Oncopeptides has 69 total employees.

  • What industry is Oncopeptides in?

    Oncopeptides’s primary industry is Biotechnology.

  • Is Oncopeptides a private or public company?

    Oncopeptides is a Public company.

  • What is Oncopeptides’s stock symbol?

    The ticker symbol for Oncopeptides is ONCO.

  • What is the current stock price of Oncopeptides?

    As of 20-Nov-2026 the stock price of Oncopeptides is $0.16.

  • What is the current market cap of Oncopeptides?

    The current market capitalization of Oncopeptides is $69.4M.

  • What is Oncopeptides’s current revenue?

    The trailing twelve month revenue for Oncopeptides is $11M.

  • Who are Oncopeptides’s competitors?

    Swedish Orphan Biovitrum, AbbVie, Karyopharm Therapeutics, CSL Behring (Biotechnology), and Cellectis are some of the 14 competitors of Oncopeptides.

  • What is Oncopeptides’s annual earnings per share (EPS)?

    Oncopeptides’s EPS for 12 months was -$0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process